CN1838945A - 罗匹尼罗的新颖制剂 - Google Patents

罗匹尼罗的新颖制剂 Download PDF

Info

Publication number
CN1838945A
CN1838945A CNA2004800241337A CN200480024133A CN1838945A CN 1838945 A CN1838945 A CN 1838945A CN A2004800241337 A CNA2004800241337 A CN A2004800241337A CN 200480024133 A CN200480024133 A CN 200480024133A CN 1838945 A CN1838945 A CN 1838945A
Authority
CN
China
Prior art keywords
dosage form
ropinirole
qualification
weight
magnesium stearate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004800241337A
Other languages
English (en)
Chinese (zh)
Inventor
朱利安·韦斯特鲁普
佩塔·E·波洛克
戴维·J·亚蒂斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Cork Ltd
Original Assignee
SmithKline Beecham Cork Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Cork Ltd filed Critical SmithKline Beecham Cork Ltd
Publication of CN1838945A publication Critical patent/CN1838945A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CNA2004800241337A 2003-08-22 2004-08-19 罗匹尼罗的新颖制剂 Pending CN1838945A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0319874.4 2003-08-22
GBGB0319874.4A GB0319874D0 (en) 2003-08-22 2003-08-22 Novel formulation

Publications (1)

Publication Number Publication Date
CN1838945A true CN1838945A (zh) 2006-09-27

Family

ID=28460214

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2004800241337A Pending CN1838945A (zh) 2003-08-22 2004-08-19 罗匹尼罗的新颖制剂

Country Status (19)

Country Link
US (1) US20070059365A1 (cg-RX-API-DMAC7.html)
EP (1) EP1656118A2 (cg-RX-API-DMAC7.html)
JP (1) JP2007503414A (cg-RX-API-DMAC7.html)
KR (1) KR20060120596A (cg-RX-API-DMAC7.html)
CN (1) CN1838945A (cg-RX-API-DMAC7.html)
AR (1) AR045289A1 (cg-RX-API-DMAC7.html)
AU (1) AU2004266072A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0413632A (cg-RX-API-DMAC7.html)
CA (1) CA2536414A1 (cg-RX-API-DMAC7.html)
GB (1) GB0319874D0 (cg-RX-API-DMAC7.html)
IL (1) IL173440A0 (cg-RX-API-DMAC7.html)
IS (1) IS8352A (cg-RX-API-DMAC7.html)
MA (1) MA27998A1 (cg-RX-API-DMAC7.html)
MX (1) MXPA06002023A (cg-RX-API-DMAC7.html)
NO (1) NO20061291L (cg-RX-API-DMAC7.html)
RU (1) RU2006109010A (cg-RX-API-DMAC7.html)
TW (1) TW200517107A (cg-RX-API-DMAC7.html)
WO (1) WO2005018605A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200600719B (cg-RX-API-DMAC7.html)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011032416A1 (zh) * 2009-09-19 2011-03-24 浙江华海药业股份有限公司 含有多巴胺受体激动剂的药物组合物
CN102395276A (zh) * 2009-02-13 2012-03-28 罗马克实验室有限公司 硝唑尼特的控制释放药物剂型
CN101574341B (zh) * 2008-05-05 2012-12-19 北京德众万全医药科技有限公司 一种罗匹尼罗的口服固体药物组合物
CN104188931A (zh) * 2014-08-25 2014-12-10 泰州越洋医药开发有限公司 一种盐酸罗匹尼罗固体口服控释片剂及其制备方法
CN104473893A (zh) * 2014-11-21 2015-04-01 哈尔滨圣吉药业股份有限公司 一种盐酸罗匹尼罗缓释片及其制备方法

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101336109A (zh) * 2005-12-20 2008-12-31 赛诺科学股份公司 用于治疗和诊断下肢不宁综合征的方法与组合物
US20100136125A1 (en) * 2006-12-28 2010-06-03 Jacobus Pharmaceutical Company, Inc. Method of treating inflammatory bowel disease
EP2022496A1 (en) * 2007-07-16 2009-02-11 Ranbaxy Laboratories Limited Stable ropinirole compositions
WO2009023761A2 (en) * 2007-08-14 2009-02-19 Dr. Reddy's Laboratories Ltd. Pharmaceutical compositions comprising ropinirole
US20090076124A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched ropinirole
WO2009078034A2 (en) * 2007-11-26 2009-06-25 Rubicon Research Private Limited Oral disintegrating tablets of ropinirole hydrochloride
SI22849A (sl) * 2008-08-01 2010-02-26 Krka, Tovarna Zdravil, D.D., Novo Mesto Ropinirolni pripravek
WO2010015911A1 (en) * 2008-08-06 2010-02-11 Torrent Pharmaceuticals Limited Sustained release pharmaceutical compositions of ropinirole and process for preparation thereof
WO2010023693A2 (en) * 2008-09-01 2010-03-04 Lupin Limited Novel controlled release compositions of ropinirole
EP2346494A2 (en) 2008-09-29 2011-07-27 Wockhardt Limited Extended release dosage form of ropinirole
WO2010044108A2 (en) 2008-10-17 2010-04-22 Rubicon Research Private Limited Controlled release formulations of ropinirole
KR101068476B1 (ko) * 2009-12-29 2011-09-28 환인제약 주식회사 로피니롤 경구 투여용 서방성 제제
GR1007629B (el) 2011-07-13 2012-06-29 Φαρματεν Αβεε, Φαρμακευτικο σκευασμα ελεγχομενης αποδεσμευσης ενος μη εργολινικου αγωνιστη της ντοπαμινης
WO2013111070A1 (en) * 2012-01-23 2013-08-01 Ranbaxy Laboratories Limited In-situ multilayered tablet technology
ITFI20130189A1 (it) * 2013-08-05 2015-02-06 Valpharma Internat S P A Una composizione farmaceutica contenente ropinirolo hcl somministrabile per via orale e metodo di produzione.
US9463889B2 (en) * 2013-10-25 2016-10-11 Medtronic, Inc. Prefilled reservoir apparatus for ambulatory infusion device
WO2016204939A1 (en) 2015-06-19 2016-12-22 Biotie Therapies, Inc. Controlled-release tozadenant formulations
CN114727986B (zh) * 2019-11-26 2025-05-30 久光制药株式会社 含罗匹尼罗的贴附剂的粘合剂层保持力提升方法及含罗匹尼罗的保持力改善的贴附剂
WO2021129600A1 (zh) * 2019-12-23 2021-07-01 江苏恒瑞医药股份有限公司 一种jak激酶抑制剂药物组合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1188212B (it) * 1985-12-20 1988-01-07 Paolo Colombo Sistema per il rilascio a velocita' controllata di sostanze attive
IT1237904B (it) * 1989-12-14 1993-06-18 Ubaldo Conte Compresse a rilascio a velocita' controllata delle sostanze attive
IT1265240B1 (it) * 1993-11-30 1996-10-31 Ekita Investments Nv Compressa farmaceutica a rilascio controllato, di forma lenticolare
US20010029262A1 (en) * 1998-06-29 2001-10-11 Sethi Kapil Dev Method of treatment or prophylaxis
AR030557A1 (es) * 2000-04-14 2003-08-27 Jagotec Ag Una tableta en multicapa de liberacion controlada y metodo de tratamiento
GB0125088D0 (en) * 2001-10-18 2001-12-12 Smithkline Beecham Cork Ltd New use
CA2489865C (en) * 2002-06-25 2012-05-08 Acrux Dds Pty Ltd Transdermal delivery rate control using amorphous pharmaceutical compositions

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101574341B (zh) * 2008-05-05 2012-12-19 北京德众万全医药科技有限公司 一种罗匹尼罗的口服固体药物组合物
CN102395276A (zh) * 2009-02-13 2012-03-28 罗马克实验室有限公司 硝唑尼特的控制释放药物剂型
WO2011032416A1 (zh) * 2009-09-19 2011-03-24 浙江华海药业股份有限公司 含有多巴胺受体激动剂的药物组合物
CN102470123A (zh) * 2009-09-19 2012-05-23 浙江华海药业股份有限公司 含有多巴胺受体激动剂的药物组合物
CN102470123B (zh) * 2009-09-19 2013-08-28 浙江华海药业股份有限公司 含有多巴胺受体激动剂的药物组合物
CN104188931A (zh) * 2014-08-25 2014-12-10 泰州越洋医药开发有限公司 一种盐酸罗匹尼罗固体口服控释片剂及其制备方法
CN104473893A (zh) * 2014-11-21 2015-04-01 哈尔滨圣吉药业股份有限公司 一种盐酸罗匹尼罗缓释片及其制备方法

Also Published As

Publication number Publication date
RU2006109010A (ru) 2006-08-10
JP2007503414A (ja) 2007-02-22
TW200517107A (en) 2005-06-01
AR045289A1 (es) 2005-10-19
BRPI0413632A (pt) 2006-10-17
WO2005018605A3 (en) 2005-11-03
US20070059365A1 (en) 2007-03-15
GB0319874D0 (en) 2003-09-24
WO2005018605A2 (en) 2005-03-03
AU2004266072A1 (en) 2005-03-03
IS8352A (is) 2006-03-14
IL173440A0 (en) 2006-06-11
ZA200600719B (en) 2007-03-28
EP1656118A2 (en) 2006-05-17
KR20060120596A (ko) 2006-11-27
MA27998A1 (fr) 2006-07-03
CA2536414A1 (en) 2005-03-03
NO20061291L (no) 2006-05-16
MXPA06002023A (es) 2006-05-17

Similar Documents

Publication Publication Date Title
CN1838945A (zh) 罗匹尼罗的新颖制剂
CN1142780C (zh) 药用组合物
EP1781260B2 (en) Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
CN1092956C (zh) 含有曲马多盐的持续释放的药物配方
CN1198598C (zh) 亲水性/亲脂性聚合物骨架剂型
CN1298317C (zh) 坦洛新片剂
CN1607947A (zh) 包含3－(3－二甲基氨基－1－乙基－2－甲基－丙基)苯酚并能提供活性成分的延迟释放的药物
CN1134108A (zh) 用于控释的新颗粒及含有该颗粒的药物制剂
CN1646103A (zh) 高药物载荷片剂
CN1562024A (zh) 一种治疗心血管疾病含盐酸雷诺嗪的口服制剂
CN102036656A (zh) 含有蜡的缓释制剂
WO2018106280A1 (en) Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients
CN101442990A (zh) 消旋卡多曲的新型给药形式
CN1805738A (zh) 持续释放的二甲双胍片剂
CN1863517A (zh) 快速崩解制剂
CN1206986C (zh) 包膜马来酸三甲丁酯片剂
CN1095665C (zh) 改性释放2－甲基－5－硝基－1－咪唑基－乙醇组合物及其制备和使用方法
JP2022534159A (ja) 微細化した固形メラトニン組成物
CN1762357B (zh) 一种莫西沙星口服药物制剂及其制备方法
CN1147295C (zh) 包含托芬那酸或其医药可接受盐的快速释出片剂及其制法
TWI436760B (zh) 阿利克侖之蓋崙（ｇａｌｅｎｉｃａｌ）調配物
CN1809342A (zh) 含有氟伐他汀和羧甲纤维素钙的片剂
CN1867326A (zh) 加巴喷丁的缓释口服片剂及其制备方法
CN1203845C (zh) 含有普鲁芬的药物组合物
CN1903182A (zh) 小型化盐酸沙格雷酯经口给药制剂

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
AD01 Patent right deemed abandoned

Effective date of abandoning: 20060927

C20 Patent right or utility model deemed to be abandoned or is abandoned